# JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

> **NCT06716658** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 48 (estimated)

## Conditions studied

- Lymphoma, T-Cell
- NK-LGL Leukemia
- T-LGL Leukemia
- Cutaneous T Cell Lymphoma
- Cutaneous T Cell Lymphoma (CTCL)
- Large Granular Lymphocyte Leukemia
- Large Granular Lymphocytic Leukemia
- Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
- Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma
- Mycosis Fungoides

## Interventions

- **DRUG:** JAK1 Inhibitor

## Key facts

- **NCT ID:** NCT06716658
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-25
- **Primary completion:** 2026-11-15
- **Final completion:** 2028-11-15
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716658, "JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06716658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*